Search
Aurinia Pharmaceuticals Inc
AUPHAdd to Watchlist
14.880USD
-0.120-0.80%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.91BMarket Cap
6.68P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Aurinia Pharmaceuticals Inc is 7.43, ranking 292 out of 385 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 21.00 and a low of 13.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
17.000
Target Price
+14.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Aurinia Pharmaceuticals Inc
AUPH
7
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Aurinia Pharmaceuticals Inc's expected revenue for the next quarter?
Aurinia Pharmaceuticals Inc's expected revenue is 79.36M.
What is Aurinia Pharmaceuticals Inc's price target?
Analysts forecast that Aurinia Pharmaceuticals Inc's price target is USD 17.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 13.00.
How have Aurinia Pharmaceuticals IncAUPH's recent earnings per share performed?
The market expectation was USD 0.26, while Aurinia Pharmaceuticals IncAUPH's earnings per share (EPS) for the previous quarter was USD 1.60. EPS for the next quarter is expected at USD 0.24.
What is the analyst rating for Aurinia Pharmaceuticals Inc?
Based on the ratings of Aurinia Pharmaceuticals Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.